18F-AV-133: A selective VMAT2-binding radiopharmaceutical for PET imaging of dopaminergic neurons

PET Clinics

Volumn 5, Issue 1, 2010, Pages 75-82

  Hefti, Franz F ^a   Kung, Hank F ^b   Kilbourn, Michael R ^c   Carpenter, Alan P ^a   Clark, Christopher M ^a,b   Skovronsky, Daniel M ^a,b  

^a AVID RADIOPHARMACEUTICALS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

18F AV 133; Dopaminergic neurons; Imaging agents; PET imaging

Indexed keywords

6 FLUORODOPA F 18; 9 FLUOROPROPYL DIHYDROTETRABENAZINE F 18; AV 133; DIHYDROTETRABENAZINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; BRAIN REGION; DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EARLY DIAGNOSIS; HUMAN; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOCHEMISTRY;

EID: 77956631917     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2010.02.001     Document Type: Review

References (55)

1. D.J. Brooks The early diagnosis of Parkinson's disease Ann Neurol 44 1998 S10
2. A.L. Whone, D.L. Bailey, and P. Remy A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study J Nucl Med 45 2004 1135 1145
3. K.A. Frey, R.A. Koeppe, and M.R. Kilbourn Imaging the vesicular monoamine transporter Adv Neurol 86 2001 237
4. C.S. Lee, A. Samii, and V. Sossi In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann Neurol 47 2000 493
5. K. Tatsch Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Eur J Nucl Med Mol Imaging 29 2002 711
6. J. Booij, G. Tissingh, and A. Winogrodzka Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism Eur J Nucl Med 26 1999 171
7. J. Booij, J.D. Speelman, and M.W. Horstink The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism Eur J Nucl Med 28 2001 266
8. Y.S. Ding, J.S. Fowler, and N.D. Volkow Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain J Nucl Med 36 1995 2298
9. R.B. Innis Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and ''intrasynaptic'' transmitter Adv Pharmacol 42 1998 215
10. S.K. Meegalla, K. Ploëssl, and M.P. Kung Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents J Med Chem 41 1998 428
11. P.D. Mozley, J.S. Schneider, and P.D. Acton Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers J Nucl Med 41 2000 584
12. N.D. Volkow, Y.S. Ding, and J.S. Fowler Dopamine transporters decrease with age J Nucl Med 37 1996 554
13. N.D. Volkow, J.S. Fowler, and S.J. Gatley PET evaluation of the dopamine system of the human brain J Nucl Med 37 1996 1242
14. B.D. Ravina, J.E. Eidelberg, and J.E. Ahlskog The role of radiotracer imaging in Parkinson disease Neurology 64 2005 208
15. R. Yelin, and S. Schuldiner Vesicular neurotransmitter transporters: pharmacology, biochemistry, and molecular analysis M.E.A. Reith, Neurotransmitter transporters; structure, function, and regulation 2nd edition 2002 Humana Press Totowa (NJ) 313 354
16. W. Zhang, S. Oya, and M.P. Kung F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain J Med Chem 48 2005 5980 5988 (Pubitemid 41324608)
17. W. Zhang, S. Oya, and M.P. Kung F-18 polyetheleneglycol stilbenes as PET imaging agents for detecting Abeta aggregates in the brain Nucl Med Biol 32 2005 799 809 (Pubitemid 41505313)
18. W. Zhang, M.P. Kung, and S. Oya 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging Nucl Med Biol 34 2007 89 97
19. G. Zheng, L.P. Dwoskin, and P.A. Crooks Vesicular monoamine transporter 2: role as a novel target for drug development AAPS J 28 2006 E682 E692
20. C. Kenney, C. Hunter, and J. Jankovic Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders Mov Disord 22 2007 193 197 (Pubitemid 46374760)
21. J. Jankovic, and J. Beach Long-term effects of tetrabenazine in hyperkinetic movement disorders Neurology 48 1997 358 362
22. R. Mehvar, F. Jamali, and M.W. Watson Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies Drug Metab Dispos 15 1987 250 251
23. M.R. Kilbourn, L.C. Lee, and M.J. Heeg Absolute configuration of (1)alphadihydrotetrabenazine, an active metabolite of tetrabenazine Chirality 9 1997 59 62
24. M. Kilbourn, and P. Sherman In vivo binding of (1)-[alpha]-[3H] dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies Eur J Pharmacol 331 1997 161 168
25. J.R. Adams, H. van Netten, and M. Schulzer PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation Brain 128 2005 2777 2785
26. R.L. Albin, R.A. Koeppe, and R.D. Chervin Decreased striatal dopaminergic innervation in REM sleep behavior disorder Neurology 55 2000 1410 1412
27. N.I. Bohnen, R.L. Albin, and R.A. Koeppe Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease J Cereb Blood Flow Metab 9 2006 1198 1212
28. R.A. Koeppe, S. Gilman, and A. Joshi 11C-DTBZ and 18F-FDG PET measures in differentiating dementias J Nucl Med 46 2005 936 944
29. A. Kumar, S. Mann, and V. Sossi [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease Brain 126 2003 2648 2655
30. M.R. Kilbourn, K.A. Frey, and T. Vander Borght Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters Nucl Med Biol 23 1996 467
31. C.S. Lee, M. Schulzer, and R. de la Fuente-Fernandez Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis Arch Neurol 61 1920 2004
32. M.R. Kilbourn, B. Hockley, and L. Lee Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine (DTBZ) in rat and monkey brain Nucl Med Biol 34 2007 233 237
33. M.P. Kung, C. Hou, and R. Goswami Characterization of optically resolved 9-fluoropropyldihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters Nucl Med Biol 34 2007 239 246
34. S. Fahn Description of Parkinson's disease as a clinical syndrome Ann N Y Acad Sci 991 2003 1 14
35. S. Gilman Parkinsonian syndromes Clin Geriatr Med 22 2006 827 842
36. E. Tolosa, G. Wenning, and W. Poewe The diagnosis of Parkinson's disease Lancet Neurol 5 2006 75 86
37. C. Holmes, N. Cairns, and P. Lantos Validity of current clinical criteria for Alzheimer disease, vascular dementia and dementia with Lewy bodies Br J Psychol 174 1999 45 50
38. C.A. Luis, W. Mittenberg, and C.S. Gass Diffuse Lewy body disease: clinical, pathological, and neuropsychological review Neuropsychol Rev 9 1999 139 150
39. D.S. Geldmacher Dementia with Lewy bodies: diagnosis and clinical approach Cleve Clin J Med 71 2004 789 799
40. I.G. McKeith, D. Galalsko, and K. Kosaka Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop Neurology 47 1996 1113 1124
41. I.G. McKeith, E.K. Perry, and R.H. Perry Report of the second dementia with Lewy body international workshop Neurology 53 1999 902 905
42. I.G. McKeith Dementia with Lewy bodies Br J Psychol 180 2002 144 147
43. I.G. McKeith, D.W. Dickson, and J. Lowe Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium Neurology 65 2005 1863 1872
44. K. Stavitsky, A.M. Brickman, and N. Scarmeas The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer's disease Arch Neurol 63 2006 1450 1465
45. V. Deramecourt, S. Bombois, and C.A. Maurage Biochemical staging of synuclineopathy and amyloid deposition in dementia with Lewy bodies J Neuropathol Exp Neurol 65 2006 278 288
46. Z. Walker, E. Jaros, and R.W. Walker Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy J Neurol Neurosurg Psychiatry 78 2007 1176 1181
47. D. Aarsland, R. Perry, and J.P. Larsen Neuroleptic sensitivity in Parkinson disease and parkinsonian dementias J Clin Psychiatry 66 2005 633 637
48. A. Baskys Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms J Clin Psychiatry 65 Suppl 11 2004 16 22
49. P.E. Harris, C. Ferrara, and P. Barba VMAT2 gene expression and function as it applies to imaging beta-cell mass J Mol Med 86 2008 5 16
50. A. Maffei, Z. Liu, and P. Witkowski Identification of tissue-restricted transcripts in human islets Endocrinology 145 2004 4513 4521
51. M. Anlauf, R. Eissele, and M.K. Schafer Expression of the two isoforms of the vesicular monoamine transporter (VMAT 1 and VMAT 2) in the endocrine pancreas and pancreatic endocrine tumors J Histochem Cytochem 51 2003 1027 1040
52. A. Schmitz, C.Y. Shiue, and Q. Feng Synthesis and evaluation of fluorine-18 labeled glyburide analogs as beta-cell imaging agents Nucl Med Biol 31 2004 483 491
53. B. Wangler, S. Schneider, and O. Thews Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl) -butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic betacell mass with positron emission tomography (PET) Nucl Med Biol 31 2004 639 647
54. P.B. Clark, H.D. Gage, and C. Brown-Proctor Neurofunctional imaging of the pancreas utilizing the cholinergic PET radioligand [18F]4- fluorobenzyltrozamicol Eur J Nucl Med Mol Imaging 31 2004 258 260
55. C.S. Hampe, A.R. Wallen, and M. Schlosser Quantitative evaluation of a monoclonal antibody and its fragment as potential markers for pancreatic beta cell mass Exp Clin Endocrinol Diabetes 113 2005 381 387